INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Chiprin Jeff reported IRMD

Chief Commercial Officer · IRADIMED CORP · IRADIMED CORP — Restricted Stock Units

Side
A
Value
—
Shares
1,150
Price
—
Executed
Mar 3, 2026
Disclosed
Mar 5, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 3 executedMar 5, 2026 disclosed

IRMD · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IRMD

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    32
    SF
    Scharen-Guivel Hilda FrederiqueDirector
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$168K
    1,766 sh
    		Jun 4, 2026Jun 4, 2026
    traded Jun 4, 2026
    		+0dSEC FORM 4

    Evidence

    28
    SF
    Scharen-Guivel Hilda FrederiqueDirector
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$117K
    1,234 sh
    		Jun 4, 2026Jun 4, 2026
    traded Jun 4, 2026
    		+0dSEC FORM 4

    Evidence

    0
    SE
    Susi Roger E.Director, CEO, President, Chairman, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale · 10b5-1 plan
    		SELL$37K
    393 sh
    		Apr 14, 2026Apr 15, 2026
    traded Apr 14, 2026
    		+1dSEC FORM 4

    Evidence

    1
    SE
    Susi Roger E.Director, CEO, President, Chairman, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale · 10b5-1 plan
    		SELL$197K
    2,107 sh
    		Apr 14, 2026Apr 15, 2026
    traded Apr 14, 2026
    		+1dSEC FORM 4

    Evidence

    1
    SE
    Susi Roger E.Director, CEO, President, Chairman, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale · 10b5-1 plan
    		SELL$55K
    589 sh
    		Apr 13, 2026Apr 15, 2026
    traded Apr 13, 2026
    		+2dSEC FORM 4

    Evidence

    1
    SE
    Susi Roger E.Director, CEO, President, Chairman, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale · 10b5-1 plan
    		SELL$238K
    2,564 sh
    		Apr 13, 2026Apr 15, 2026
    traded Apr 13, 2026
    		+2dSEC FORM 4

    Evidence

    1
    SE
    Susi Roger E.Director, CEO, President, Chairman, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale · 10b5-1 plan
    		SELL$170K
    1,847 sh
    		Apr 13, 2026Apr 15, 2026
    traded Apr 13, 2026
    		+2dSEC FORM 4

    Evidence

    17
    SE
    Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$92K
    915 sh
    		Mar 24, 2026Mar 25, 2026
    traded Mar 24, 2026
    		+1dSEC FORM 4

    Evidence

    20
    SE
    Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$133K
    1,300 sh
    		Mar 23, 2026Mar 25, 2026
    traded Mar 23, 2026
    		+2dSEC FORM 4

    Evidence

    23
    SE
    Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$294K
    2,950 sh
    		Mar 23, 2026Mar 25, 2026
    traded Mar 23, 2026
    		+2dSEC FORM 4

    Evidence

    20
    SE
    Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$76K
    750 sh
    		Mar 23, 2026Mar 25, 2026
    traded Mar 23, 2026
    		+2dSEC FORM 4

    Evidence

    17
    SE
    Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$159K
    1,585 sh
    		Mar 24, 2026Mar 25, 2026
    traded Mar 24, 2026
    		+1dSEC FORM 4

    Evidence

    23
    SE
    Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$476K
    4,888 sh
    		Jan 12, 2026Jan 13, 2026
    traded Jan 12, 2026
    		+1dSEC FORM 4

    Evidence

    17
    SE
    Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$11K
    112 sh
    		Jan 12, 2026Jan 13, 2026
    traded Jan 12, 2026
    		+1dSEC FORM 4

    Evidence

    27
    SE
    Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$478K
    4,899 sh
    		Dec 29, 2025Dec 30, 2025
    traded Dec 29, 2025
    		+1dSEC FORM 4

    Evidence

    21
    SE
    Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
    IRMDIRADIMED CORP
    Open-market sale
    		SELL$9,929
    101 sh
    		Dec 29, 2025Dec 30, 2025
    traded Dec 29, 2025
    		+1dSEC FORM 4

    Evidence

    21
    SF
    Scharen-Guivel Hilda FrederiqueDirector
    IRMDIRADIMED CORP
    Grant or award
    		A—
    1,026 sh
    		Dec 11, 2025Dec 15, 2025
    traded Dec 11, 2025
    		+4dSEC FORM 4

    Evidence

    13
    SF
    Scharen-Guivel Hilda FrederiqueDirector
    IRMDIRADIMED CORP
    Option exercise
    		M—
    905 sh
    		Dec 11, 2025Dec 12, 2025
    traded Dec 11, 2025
    		+1dSEC FORM 4

    Evidence

    21
    CJ
    Chiprin JeffChief Commercial Officer
    IRMDIRADIMED CORP
    Option exercise
    		M—
    996 sh
    		Dec 11, 2025Dec 12, 2025
    traded Dec 11, 2025
    		+1dSEC FORM 4

    Evidence

    21
    CJ
    Chiprin JeffChief Commercial Officer
    IRMDIRADIMED CORP
    Tax withholding
    		F$30K
    309 sh
    		Dec 11, 2025Dec 12, 2025
    traded Dec 11, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002047489-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 3, 2026
    Published
    Mar 5, 2026
    Ingested by INSIDER
    Nov 5, 04:13 UTC
    Last re-read
    Nov 5, 04:13 UTC

    Extracted facts

    Filer
    Chiprin Jeff
    Role
    Chief Commercial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    IRADIMED CORP — Restricted Stock Units
    Ticker
    IRMD
    Shares
    1,150
    Price per share
    $0
    Execution date (reported)
    Mar 3, 2026
    Owned after transaction
    1,150 shares
    Days from execution to publication
    2

    What this establishes

    Chiprin Jeff filed this Form 4 reporting a grant or award of IRMD on Mar 3, 2026. It became public on Mar 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Commercial Officer
    Chiprin Jeffcik:0002047489
    Issuer
    IRADIMED CORPcik:0001325618

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.